No adjuvant CTx | Adjuvant CTx | Pvalue | |
---|---|---|---|
n | 181 (61) | 116 (39) | |
Gender | 0.11 | ||
Male | 115 (64) | 84 (72) | |
Female | 66 (36) | 32 (28) | |
Age [years] | 64 (30 – 88) | 63 (33 – 83) | 0.03 |
Initial stage of disease (UICC) | 0.53 | ||
I | 23 (7) | 9 (8) | |
II | 37 (21) | 17 (15) | |
III | 56 (32) | 36 (31) | |
IV | 70 (40) | 53 (46) | |
Site of primary tumor | 0.14 | ||
Colon | 95 (52) | 71 (61) | |
Rectum | 86 (47) | 45 (39) | |
CEA level [μg/l) | 12.6 (0.6 – 2032) | 18.1 (0.5 – 7606) | 0.63 |
Number of metastases | 0.72 | ||
1 | 99 (55) | 61 (53) | |
> 1 | 82 (45) | 55 (47) | |
Size of largest metastasis | 0.06 | ||
< 5 cm | 95 (52) | 48 (41) | |
≥ 5 cm | 86 (48) | 68 (59) | |
Distribution of metastases | 0.08 | ||
Unilobar | 120 (67) | 66 (57) | |
Bilobar | 60 (33) | 55 (43) | |
MSKCC clinical risk score | 0.07 | ||
≤ 2 | 111 (61) | 60 (52) | |
> 2 | 69 (39) | 56 (48) |